Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
July 23, 2010 9:42 AM 1 min read

Oppenheimer Reiterates Outperform Rating on Amdocs (DOX)

by Michael J. Zerinskas
Follow
Oppenheimer is out with a research note this morning, where it reiterates its Outperform rating on Amdocs LTD (NYSE:
DOX
); it also has a $37.00 price target on the stock. The Oppenheimer analysts said, “DOX shares came under pressure on Thursday (down 5.4%), and while we could find no convincing justification for the weakness, our discussions with investors suggest that there are two areas of concern, both of which we believe are being given too much weight. First, we believe DOX's F3Q11 results, reported 7/21, are being misinterpreted. Second, we believe there is erroneous speculation regarding DOX's prospects with key customers AT&T, Rogers and Comcast. Addressing these concerns, we believe DOX's F3Q11 results were within the guidance range, and we believe DOX's relationships with AT&T, Rogers and Comcast remain solid. We believe DOX remains an attractive investment opportunity and would be buyers on weakness.” They added, “We believe that concerns regarding alleged push-back and delays at Rogers, and risk at Comcast due to a change at the top, are also misplaced. We believe DOX's relationship with both these customers remains strong. At Comcast, we believe the incoming president is evaluating major spending projects, a standard procedure.” The analysts further noted, “We believe investors may be over-emphasizing a slowdown in sales processes in Europe (10% of revenue) which we do not believe heralds a major European slowdown. We believe no major European contracts have been recently canceled or lost. We view DOX as a leader in its space, and we view valuation, 11x our FY11E EPS of $2.39, as attractive. DOX holds ~$6.30 of cash/share. We would be buyers on weakness, and we reiterate our Outperform rating.”
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Analyst ColorPrice TargetAnalyst RatingsApplication SoftwareInformation TechnologyOppenheimer
DOX Logo
DOXAmdocs Ltd
$67.37-%
Overview
DOX Logo
DOXAmdocs Ltd
$67.37-%
Overview
Comments
Loading...